Global Sickle Cell Disease Treatment Market 2021-2025

Global Sickle Cell Disease Treatment Market 2021-2025

Technavio has been monitoring the sickle cell disease treatment market and it is poised to grow by $ 2.33 bn during 2021-2025, progressing at a CAGR of 11.36% during the forecast period. Our report on the sickle cell disease treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high prevalence of sickle cell disease and the provision of special drug designations. In addition, the high prevalence of sickle cell disease is anticipated to boost the growth of the market as well.

The sickle cell disease treatment market analysis includes the indication segment and geographical landscape.

Technavio's sickle cell disease treatment market is segmented as below:

By Indication

• Sickle cell anemia
• Others

By Geographical Landscape

• North America
• Europe
• Asia
• ROW

This study identifies the increase in screening tests on infantsas one of the prime reasons driving the sickle cell disease treatment market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on sickle cell disease treatment market covers the following areas:

• Sickle cell disease treatment market sizing
• Sickle cell disease treatment market forecast
• Sickle cell disease treatment market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading sickle cell disease treatment market vendors that include Addmedica SAS, Bristol-Myers Squibb Co., Chiesi Pharmaceuticals BV, CRISPR Therapeutics AG, Emmaus Life Sciences Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Medunik USA, Novartis AG, and Pfizer Inc. Also, the sickle cell disease treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Companies Mentioned

Addmedica SAS, Bristol-Myers Squibb Co., Chiesi Pharmaceuticals BV, CRISPR Therapeutics AG, Emmaus Life Sciences Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Medunik USA, Novartis AG, Pfizer Inc.